Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5446777 | 0.83 | ALDH1A1 (0.68) | ALDH1A1HPGDKDM4EMTNR1AMTNR1B | |
| SCHEMBL3566514 | 0.83 | ALDH1A1 (0.83) | ALDH1A1HPGDKDM4EMTNR1AMTNR1B | |
| SCHEMBL4229520 | 0.81 | BRPF1 (0.67) | ALDH1A1HPGDKDM4EPIM3MAPK1 | |
| SCHEMBL9936554 | 0.81 | NR4A2 (0.70) | ALDH1A1HPGDKDM4EPIM3MTNR1A | |
| SCHEMBL14410811 | 0.81 | ALDH1A1 (0.65) | ALDH1A1HPGDKDM4EPIM3MTNR1A | |
| SCHEMBL2037236 | 0.79 | PIM3 (0.59) | PIM3MAPK1BRPF1RAB9A | |
| SCHEMBL6029339 | 0.78 | ALDH1A1 (0.62) | ALDH1A1HPGDKDM4EMTNR1AMTNR1B | |
| SCHEMBL27436908 | 0.78 | ALDH1A1 (0.65) | ALDH1A1HPGDKDM4EMTNR1AMTNR1B | |
| SCHEMBL28289155 | 0.78 | ALDH1A1 (0.73) | ALDH1A1HPGDKDM4EMTNR1AMTNR1B | |
| SCHEMBL7838694 | 0.78 | PIM3 (0.58) | ALDH1A1KDM4EPIM3MAPK1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1708992-B1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2007-08-08 | — | — | EP | claimed |
| US-7700634-B2 | (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor | N.V. ORGANON (NL) | 2010-04-20 | — | — | US | disclosed |
| EP-1725232-B1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | ORGANON NV (NL) | 2008-01-23 | — | — | EP | disclosed |
| US-7304064-B2 | 1-[(indol-3-yl)carbonyl]piperazine derivatives | N.V. ORGANON (NL) | 2007-12-04 | — | — | US | disclosed |
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | MERCK SHARP & DOHME B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| EP-1549637-B1 | 1- (INDOL-3-YL)CARBONYL PIPERAZINE DERIVATIVES | ORGANON NV (NL) | 2007-05-02 | — | — | EP | disclosed |
| EP-1725232-A1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | N.V. Organon (NL) | 2006-11-29 | — | — | EP | disclosed |
| US-20050250760-A1 | 1-[(Indol-3-yl)carbonyl]piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2005-11-10 | — | — | US | disclosed |
| WO-2005089754-A1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | AKZO NOBEL N.V. (NL) | 2005-09-29 | — | — | WO | disclosed |
| EP-1549637-A1 | 1- (INDOL-3-YL)CARBONYL PIPERAZINE DERIVATIVES | Akzo Nobel N.V. (NL) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004000832-A1 | 1-[(INDOL-3-YL)CARBONYL] PIPERAZINE DERIVATIVES | AKZO NOBEL N.V. (NL) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250760-A1 | 1-[(Indol-3-yl)carbonyl]piperazine derivatives | IDO1, OPRL1, OPRK1 | ALDH1A1 689/4885HPGD 1291/4885KDM4E 1502/4885 |
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | CNR1, CNR2, OPRL1 | ALDH1A1 1616/4885HPGD 682/4885KDM4E 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.